COST

986.79

-0.92%↓

158.44

+1.12%↑

78.87

-0.78%↓

183.37

+0.45%↑

PEP

164.53

+0.12%↑

COST

986.79

-0.92%↓

158.44

+1.12%↑

78.87

-0.78%↓

183.37

+0.45%↑

PEP

164.53

+0.12%↑

COST

986.79

-0.92%↓

158.44

+1.12%↑

78.87

-0.78%↓

183.37

+0.45%↑

PEP

164.53

+0.12%↑

COST

986.79

-0.92%↓

158.44

+1.12%↑

78.87

-0.78%↓

183.37

+0.45%↑

PEP

164.53

+0.12%↑

COST

986.79

-0.92%↓

158.44

+1.12%↑

78.87

-0.78%↓

183.37

+0.45%↑

PEP

164.53

+0.12%↑

Home・Akciju saraksts・Lifecore Biomedical Inc

Lifecore Biomedical Inc

Slēgts

SektorsPatēriņa aizsardzības

7.18 -0.42

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

7.01

Max

7.21

Galvenie mērījumi
By Trading Economics
Ienākumi	-7.9M -10M
Pārdošana	-5.3M 31M
Peļņas marža	-32.116
Darbinieki	406

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 20. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-16M 225M
Iepriekšējā atvēršanas cena	7.6
Iepriekšējā slēgšanas cena	7.18

Lifecore Biomedical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 19. febr. 23:47 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 19. febr. 23:47 UTC

Tirgus saruna

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

2026. g. 19. febr. 23:39 UTC

Iegādes, apvienošanās, pārņemšana

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

2026. g. 19. febr. 23:38 UTC

Peļņas

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

2026. g. 19. febr. 23:38 UTC

Peļņas

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

2026. g. 19. febr. 23:38 UTC

Peļņas

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

2026. g. 19. febr. 23:37 UTC

Tirgus saruna

Gold Edges Lower on Possible Position Adjustment -- Market Talk

2026. g. 19. febr. 23:34 UTC

Peļņas

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

2026. g. 19. febr. 23:34 UTC

Peļņas

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

2026. g. 19. febr. 23:33 UTC

Peļņas

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

2026. g. 19. febr. 23:33 UTC

Peļņas

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

2026. g. 19. febr. 22:13 UTC

Tirgus saruna

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

2026. g. 19. febr. 22:08 UTC

Peļņas

Fairfax Financial 4Q Rev $8.11B >FFH.T

2026. g. 19. febr. 22:07 UTC

Peļņas

Eldorado Gold 4Q EPS $1.19 >ELD.T

2026. g. 19. febr. 22:06 UTC

Peļņas

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

2026. g. 19. febr. 22:05 UTC

Peļņas

Eldorado Gold 4Q Adj EPS 63c >ELD.T

2026. g. 19. febr. 22:05 UTC

Peļņas

Eldorado Gold 4Q Rev $577.2M >ELD.T

2026. g. 19. febr. 22:04 UTC

Peļņas

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

2026. g. 19. febr. 22:04 UTC

Peļņas

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

2026. g. 19. febr. 21:50 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 19. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 19. febr. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 19. febr. 21:43 UTC

Peļņas

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

2026. g. 19. febr. 21:42 UTC

Iegādes, apvienošanās, pārņemšana

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

2026. g. 19. febr. 21:42 UTC

Peļņas

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

2026. g. 19. febr. 21:41 UTC

Peļņas

Correct: St Barbara 1H Net Loss A$249,000

2026. g. 19. febr. 21:40 UTC

Peļņas

St Barbara 1H Net Loss A$249 Million

2026. g. 19. febr. 21:39 UTC

Peļņas

Perseus Mining Reaffirms FY26 Production, AISC Guidance

2026. g. 19. febr. 21:37 UTC

Peļņas

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

2026. g. 19. febr. 21:37 UTC

Peļņas

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Salīdzinājums

Cenas izmaiņa

Lifecore Biomedical Inc Prognoze

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Lifecore Biomedical Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.